We are pleased to announce WuXi has completed the acquisition of HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO). Shanghai-based HD Biosciences’ plate-based pharmacology and screening capability and AGMTM based target validation are industry leading platforms.

This business combination is an important step in WuXi’s development of the most comprehensive capability and technology platform in industry to enable anyone, and any company to discover and develop better medicines and healthcare products for patients, and to realize our vision that ‘every drug can be made and every disease can be treated.’